Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$3.47 +13.0%	$2.54	$1.78 ▼ $11.40	$132.68M	2.52	380,326 shs	852,400 shs
MRVI Maravai LifeSciences	$2.38 +4.8%	$2.13	$1.67 ▼ $10.03	$578.08M	0.25	2.33 million shs	2.26 million shs
OPT Opthea	$3.41 +7.2%	$3.41	$1.79 ▼ $6.30	$524.84M	1.18	26,406 shs	3,000 shs
TSHA Taysha Gene Therapies	$2.41 -1.2%	$2.41	$1.05 ▼ $3.31	$523.78M	1.04	3.04 million shs	2.33 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+13.03%	+19.24%	+34.50%	+73.50%	-52.27%
MRVI Maravai LifeSciences	+4.85%	+18.41%	+6.73%	+0.85%	-65.71%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+81.38%
TSHA Taysha Gene Therapies	-1.23%	-6.23%	-7.66%	+24.87%	+18.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KYTX Kyverna Therapeutics	2.9849 of 5 stars	3.6	3.0	0.0	3.3	1.7	0.6
MRVI Maravai LifeSciences	3.7502 of 5 stars	3.1	3.0	4.4	1.5	0.8	0.6
OPT Opthea	0.469 of 5 stars	1.1	0.0	0.0	3.3	0.8	0.6
TSHA Taysha Gene Therapies	3.298 of 5 stars	4.5	1.0	0.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	433.14% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	178.94% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
TSHA Taysha Gene Therapies	3.00	Buy	$8.00	231.95% Upside

Current Analyst Ratings Breakdown

Latest KYTX, TSHA, OPT, and MRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
4/28/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYTX Kyverna Therapeutics	$7.03M	21.33	N/A	N/A	$6.17 per share	0.56
MRVI Maravai LifeSciences	$259.18M	2.34	$0.65 per share	3.67	$2.28 per share	1.04
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09
TSHA Taysha Gene Therapies	$8.33M	62.10	N/A	N/A	$0.35 per share	6.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest KYTX, TSHA, OPT, and MRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYTX Kyverna Therapeutics	N/A	7.44	7.44
MRVI Maravai LifeSciences	0.60	5.96	5.17
OPT Opthea	N/A	1.57	N/A
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYTX Kyverna Therapeutics	18.08%
MRVI Maravai LifeSciences	50.25%
OPT Opthea	55.95%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
KYTX Kyverna Therapeutics	22.00%
MRVI Maravai LifeSciences	2.11%
OPT Opthea	3.20%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	33.71 million	Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

KYTX, TSHA, OPT, and MRVI Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26 at 4:46 PM | marketbeat.com

Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $7.57

June 24 at 2:29 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 4, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Industrials Stocks Standing Out for Growth and Analyst Optimism
By Nathan Reiff | June 4, 2025
View 3 Industrials Stocks Standing Out for Growth and Analyst Optimism
Silver's Options Sizzle: Are Traders Betting on a Breakout?
By Jeffrey Neal Johnson | June 5, 2025
View Silver's Options Sizzle: Are Traders Betting on a Breakout?
The Other AI Chipmaker: Why Marvell's Dip Is a Buy
By Jeffrey Neal Johnson | June 12, 2025
View The Other AI Chipmaker: Why Marvell's Dip Is a Buy
AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
By Jeffrey Neal Johnson | June 5, 2025
View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
Reddit Stock Ignites: Surge in Call Options Signals Big Bet
By Gabriel Osorio-Mazilli | June 24, 2025
View Reddit Stock Ignites: Surge in Call Options Signals Big Bet

KYTX, TSHA, OPT, and MRVI Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

$3.47 +0.40 (+13.03%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.56 +0.09 (+2.59%)

As of 06/26/2025 07:17 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Maravai LifeSciences NASDAQ:MRVI

$2.38 +0.11 (+4.85%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.39 +0.01 (+0.42%)

As of 06/26/2025 04:54 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 06/25/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Taysha Gene Therapies NASDAQ:TSHA

$2.41 -0.03 (-1.23%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.37 -0.04 (-1.66%)

As of 06/26/2025 06:11 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time